Tag - MITO

Markets

Maxim starts Stealth BioTherapeutics at buy; PT $3

Maxim Group initiated coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and price target of $3. The stock closed at $1.56 on June 30. Stealth is developing compounds that target mitochondrial...

July 1, 2021

Markets

Roth starts Stealth BioTherapeutics at buy; PT $9

Roth Capital Partners launched coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and $9 price target. The stock closed at $1.59 on April 13. Stealth is focused on developing drugs targeted for rare...

April 14, 2020

Developments

Stealth gets FDA rare pediatric disease designation for elamipretide

Stealth BioTherapeutics’ (NASDAQ:MITO) elamipretide received FDA rare pediatric disease designation for the treatment of Barth syndrome. Barth syndrome is a very rare genetic condition characterized by cardiac...

March 3, 2020

Tag - MITO

Maxim starts Stealth BioTherapeutics at buy; PT $3

Roth starts Stealth BioTherapeutics at buy; PT $9

Stealth gets FDA rare pediatric disease designation for elamipretide

General

More